Akebia Therapeutics, Inc. Appoints Michael Wyzga To Its Board Of Directors

Akebia Therapeutics, a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease, today announced the appointment of Michael S. Wyzga as an independent member to the company's Board of Directors. Mr. Wyzga will serve as the Chairman of Akebia’s Audit Committee.

Help employers find you! Check out all the jobs and post your resume.